Andrew Cuthbertson commenced as a member of Council on 1 January 2020.
Andrew is a Non-Executive Director (since 2018) on the CSL Limited board, where he chairs the Innovation and Development Committee. Andrew served as the CSL R&D Director and Chief Scientific Officer for over 20 years.
He trained in Medicine and Science at the University of Melbourne gaining a BMedSci, and MBBS, and then completed a PhD in Immunology at the Walter and Eliza Hall Institute. In 2016, Andrew was made an Enterprise Professor, Faculty of Medicine, Dentistry and Health Sciences, at the University of Melbourne.
Andrew conducted molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He was also employed at Genentech Inc. in San Francisco, working on anti–VEGF therapy for age-related macular degeneration.
In 1990, Andrew received the Australian Academy of Science Gottschalk medal and in 1998 the Chibret International Award for Ophthalmologic Research.
Since 2017, Andrew has been on the Board for the Centre for Eye Research Australia (CERA), the leading eye research institute in Australia, and an affiliate of the University of Melbourne. Andrew is also a Board member of the Grattan Institute.
Andrew is a Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and a Fellow of the Australian Academy of Technological Sciences, and has been a member of the NHMRC Council.
In 2016, Andrew was made an Officer of the Order of Australia (AO).